Literature DB >> 12478295

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.

Peter D Kwong1, Michael L Doyle, David J Casper, Claudia Cicala, Stephanie A Leavitt, Shahzad Majeed, Tavis D Steenbeke, Miro Venturi, Irwin Chaiken, Michael Fung, Hermann Katinger, Paul W I H Parren, James Robinson, Donald Van Ryk, Liping Wang, Dennis R Burton, Ernesto Freire, Richard Wyatt, Joseph Sodroski, Wayne A Hendrickson, James Arthos.   

Abstract

The ability of human immunodeficiency virus (HIV-1) to persist and cause AIDS is dependent on its avoidance of antibody-mediated neutralization. The virus elicits abundant, envelope-directed antibodies that have little neutralization capacity. This lack of neutralization is paradoxical, given the functional conservation and exposure of receptor-binding sites on the gp120 envelope glycoprotein, which are larger than the typical antibody footprint and should therefore be accessible for antibody binding. Because gp120-receptor interactions involve conformational reorganization, we measured the entropies of binding for 20 gp120-reactive antibodies. Here we show that recognition by receptor-binding-site antibodies induces conformational change. Correlation with neutralization potency and analysis of receptor-antibody thermodynamic cycles suggested a receptor-binding-site 'conformational masking' mechanism of neutralization escape. To understand how such an escape mechanism would be compatible with virus-receptor interactions, we tested a soluble dodecameric receptor molecule and found that it neutralized primary HIV-1 isolates with great potency, showing that simultaneous binding of viral envelope glycoproteins by multiple receptors creates sufficient avidity to compensate for such masking. Because this solution is available for cell-surface receptors but not for most antibodies, conformational masking enables HIV-1 to maintain receptor binding and simultaneously to resist neutralization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12478295     DOI: 10.1038/nature01188

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  466 in total

1.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

2.  CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5.

Authors:  Aarti Raja; Miro Venturi; Peter Kwong; Joseph Sodroski
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Evolution of two amino acid positions governing broad neutralization resistance in a strain of feline immunodeficiency virus over 7 years of persistence in cats.

Authors:  Mauro Pistello; Donatella Matteucci; Simone Giannecchini; Francesca Bonci; Olimpia Sichi; Silvano Presciuttini; Mauro Bendinelli
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

4.  Blocking the docking of HIV-1.

Authors:  Aine McKnight; Robin A Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-08       Impact factor: 11.205

5.  Binding thermodynamics of the N-terminal peptide of the CCR5 coreceptor to HIV-1 envelope glycoprotein gp120.

Authors:  Evan T Brower; Arne Schön; Jeffrey C Klein; Ernesto Freire
Journal:  Biochemistry       Date:  2009-02-03       Impact factor: 3.162

6.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

7.  Entropy calculation of HIV-1 Env gp120, its receptor CD4, and their complex: an analysis of configurational entropy changes upon complexation.

Authors:  Shang-Te D Hsu; Christine Peter; Wilfred F van Gunsteren; Alexandre M J J Bonvin
Journal:  Biophys J       Date:  2004-10-15       Impact factor: 4.033

8.  Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors:  Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4.

Authors:  Theresa L-Y Chang; Chia-Hwa Chang; David A Simpson; Qiang Xu; Patrick K Martin; Laurel A Lagenaur; Gary K Schoolnik; David D Ho; Sharon L Hillier; Mark Holodniy; John A Lewicki; Peter P Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-12       Impact factor: 11.205

10.  Two-dimensional gel-based approaches for the assessment of N-Linked and O-GlcNAc glycosylation in human and simian immunodeficiency viruses.

Authors:  David R M Graham; Megan J Mitsak; Steven T Elliott; Dawn Chen; Stephen A Whelan; Gerald W Hart; Jennifer E Van Eyk
Journal:  Proteomics       Date:  2008-12       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.